Increasing cure rates of solid tumors by immune checkpoint inhibitors

HIGHLIGHTS

• who: Weijie Ma from the NY, USA Ellis Fischel Cancer Center, University of Missouri, Hospital Dr have published the research: Increasing cure rates of solid tumors by immune checkpoint inhibitors, in the Journal: (JOURNAL)
• what: After the approval of the first immune checkpoint inhibitor (ICI), ipilimumab, targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4), initial investigations with ICIs were focused on salvage therapy for metastatic cancers. In this scenario, adjuvant pembrolizumab is commonly recommended based on the KEYNOTE-716 trial, although surveillance and enrollment in a clinical trial are reasonable alternatives.
• future: As . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.